Prescription medicine
Soybean oil Brand names: Intralipid, Nutrilipid
Soybean oil (Intralipid) is a prescription medicine with an FDA approval on record since 1975. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the soybean oil FDA label on DailyMed (effective November 19, 2025, Fresenius Kabi USA, LLC); the NDA 17643 record on Drugs@FDA; every soybean oil label on DailyMed.
Highlights of the record
FDA label of November 19, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageIntralipid ® is indicated as a source of calories and essential fatty acids for adult and pediatric patients requiring parenteral nutrition (PN) and as a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).
Forms and strengths
- 10 g/100ml
- 20 g/100ml
- 30 g/100ml
Emulsion; injection (solution).
On the market
- Earliest approval on file
- October 7, 1975 Intralipid 10%, Fresenius; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 5 of which 0 under generic applications, 5 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,386 through July 30, 2026
What is soybean oil used for?
From the label: indications and usageIntralipid ® is indicated as a source of calories and essential fatty acids for adult and pediatric patients requiring parenteral nutrition (PN) and as a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD). Intralipid is indicated as a source of calories and essential fatty acids for adult and pediatric patients requiring parenteral nutrition (PN) and as a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).
FDA pharmacologic class: Lipid Emulsion.
Source: FDA drug label (Intralipid), Fresenius Kabi USA, LLC, effective November 19, 2025 (SPL set 61e025f1-a38e-4af2-9e18-13ea12977cf5), via openFDA; the full label on DailyMed
Is there a generic for soybean oil (Intralipid)?
No generic soybean oil is approved (Drugs@FDA, October 8, 2026).
- 1975 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the soybean oil label say about other medicines?
The soybean oil label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Thiamine | warnings and precautions | Thiamine deficiency and fluid retention may also develop. |
| Warfarin | drug interactions | DRUG INTERACTIONS Soybean oil in Intralipid contains vitamin K 1 which may counteract the anticoagulant activity of vitamin K antagonists such as warfarin. |
Source: FDA drug label (Intralipid), Fresenius Kabi USA, LLC, effective November 19, 2025 (SPL set 61e025f1-a38e-4af2-9e18-13ea12977cf5), via openFDA; the full label on DailyMed
What do FAERS reports show for soybean oil?
The FDA Adverse Event Reporting System holds 1,386 reports that list soybean oil among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 153 are coded as a death and 397 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other lipid emulsions
- the pharmacologic class, with prices and generics
- Soybean oil side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other